Clinical Scorecard: FDA declines approval of ivonescimab for previously treated advanced NSCLC
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: FDA rejects ivonescimab for lung cancer |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | Patients or participants described in the source article. |
| Care Setting | Proposed treatment for locally advanced or metastatic NSCLC previously treated with EGFR TKIs; ivonescimab is not approved in the United States. |
Key Highlights
- Summit Therapeutics reported that the FDA issued a Complete Response Letter declining approval of ivonescimab plus platinum-containing chemotherapy for the proposed NSCLC indication.
- According to Summit, the FDA determined that substantial evidence of effectiveness had not been established without a statistically significant overall survival improvement and that progression-free survival benefit alone did not support a favorable benefit-risk profile.
- In the phase 3 HARMONi trial, the combination met dual primary progression-free survival endpoints.
- Overall survival showed a favorable trend but did not reach statistical significance.
- Summit reported that ivonescimab remains investigational in the United States and has marketing authorization in China.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
HARMONi enrolled patients with EGFR-mutated, locally advanced or metastatic nonsquamous NSCLC previously treated with a third-generation EGFR TKI.
The trial compared ivonescimab plus platinum-containing chemotherapy with placebo plus chemotherapy. The FDA declined approval for the proposed indication; ivonescimab is not approved in the United States.
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
